Helix

San Mateo – October 19, 2026 -- Helix will present three-year outcomes from CDC Tier 1 genomic screening of 527,000 participants at the opening plenary of the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20-24 in Montreal. The company says its GenoSphereTM resource now holds more than 620,000 paired EHR, claims and genomics records.

Helix Research Network supplies the plenary data from 17 health systems

The plenary study draws on the Helix Research Network (HRN), which Helix describes as the world's largest precision health network. All 17 member health systems offer CDC Tier 1 primary screening to every patient who enrolls in research. The study examines how surfacing previously undiagnosed genetic risk can improve screening and preventive care across diverse health systems.

Cassie Hajek, MD, Medical Director, will deliver the talk on Tuesday, October 20, from 5:57 to 6:15 p.m. ET in Room 517.

San Mateo, Calif. – September 16, 2026 -- Helix has launched Whole Exome+ Sequencing (WES+), a diagnostic test that combines exome sequencing, mitochondrial genome analysis, and genome-wide digital karyotype into a single order for patients with unexplained developmental delay, neurological conditions, and rare genetic disease.

WES+ integrates four diagnostic capabilities in one order

The test covers 99% of clinically relevant exome regions, includes mitochondrial testing that other labs typically bill as a separate add-on, and performs high-resolution chromosomal copy number analysis via a digital karyotype. Helix says the digital karyotype feature may eliminate the need for a standalone chromosomal microarray (CMA) in many clinical scenarios, though the company notes CMA or additional cytogenetic testing may still be clinically indicated in some cases.